Fresh analysis reveals that patients who stop using popular weight-loss injections like semaglutide or tirzepatide may regain reduced body mass far faster than those who halt traditional lifestyle programs.
Published data in a prominent health publication shows that while obese people frequently drop substantial amounts of their body weight while undergoing treatment, the mass is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals using these treatments should be informed of the risk of rapid weight regain when the treatment concludes," cautioned researcher Dr. Susan Jebb.
This pace of regain implies a return to original weight in about 18 months.
Comparing Therapies
The study, which reviewed dozens of studies involving over 9,000 of participants, compared the outcomes of these new drugs with other pills.
Scientists emphasize that individuals who lose weight through lifestyle changes alone generally have a slower creep back—perhaps 100 grams monthly—post-intervention.
Explaining the Fast Regain
Experts propose the mode of action of the jabs accounts for the heightened regain.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of the hormone levels far above than normal might result in the system to generate a reduced amount of its endogenous GLP-1, and could lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication leads to hunger is no longer kept in check, making excessive eating much more probable."
An Ongoing Disease?
Health authorities suggest the injections for people with obesity-related medical conditions, alongside recommended lifestyle changes.
A number of clinicians argue that, due to the likelihood of weight regain, the treatment should be considered life-long.
This view is echoed by drug manufacturers, who say that the findings "underscore the long-term nature of excess weight," similar to managing diseases like diabetes.
User Accounts
Users who have discontinued the jabs describe a powerful return of appetite.
"I experienced something flipping and you're instantly extremely hungry," recalled one woman.
This difficulty is worsened if patients have not established lasting lifestyle or habit modifications during treatment.
Significant Use
Survey data indicate that millions of people in the UK have tried these injections in the past year, with interest continuing to grow.
- Use is more common among women compared to males.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
In conclusion, experts caution that while GLP-1 drugs are effective agents for weight loss, they are not a permanent fix and lasting health benefits hinges on integrated behavioural support.
